SCHEMBL24258034

SCHEMBL24258034

Cc1nc2ccc(-c3ccc(=O)[nH]c3)cc2n1Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.69
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
DCTPP1 Q9H773 2/20 0.46
BRD4 O60885 2/20 0.45
KDM4E B2RXH2 1/20 0.45
PPARG P37231 6/20 0.44
TYMS P04818 1/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
JAK2 O60674 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SPHK1 Q9NYA1 1/20 0.42
GALR3 O60755 1/20 0.42
NR2F2 P24468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13508771 0.81 KCNH2 (1.00) KCNH2KMT2AMEN1ALDH1A1HTT
SCHEMBL13508758 0.81 KCNH2 (0.86) KCNH2KMT2AMEN1ALDH1A1HTT
SCHEMBL16756523 0.79 MEN1 (0.44) KCNH2KMT2AMEN1ALDH1A1HTT
SCHEMBL24258041 0.76 KCNH2 (0.56) KCNH2ALDH1A1HTTBRD4
SCHEMBL6172847 0.74 PPARG (0.60) DCTPP1PPARG
SCHEMBL26004957 0.74 DCTPP1 (0.46) KCNH2KMT2AHTTDCTPP1BRD4
SCHEMBL16756407 0.74 HPGD (0.44) KCNH2KMT2AMEN1ALDH1A1HTT
SCHEMBL5958823 0.73 PPARG (0.57) KMT2AHTTDCTPP1PPARGRAB9A
SCHEMBL18918998 0.73 KCNH2 (0.48) KCNH2KMT2AMEN1ALDH1A1HTT
SCHEMBL16756351 0.72 MEN1 (0.48) KCNH2KMT2AMEN1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 KCNH2 4853/4885KMT2A 1212/4885MEN1 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.